1. Home
  2. WLDN vs KROS Comparison

WLDN vs KROS Comparison

Compare WLDN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WLDN
  • KROS
  • Stock Information
  • Founded
  • WLDN 1964
  • KROS 2015
  • Country
  • WLDN United States
  • KROS United States
  • Employees
  • WLDN N/A
  • KROS N/A
  • Industry
  • WLDN Military/Government/Technical
  • KROS Biotechnology: Pharmaceutical Preparations
  • Sector
  • WLDN Consumer Discretionary
  • KROS Health Care
  • Exchange
  • WLDN Nasdaq
  • KROS Nasdaq
  • Market Cap
  • WLDN 581.0M
  • KROS 589.8M
  • IPO Year
  • WLDN 2006
  • KROS 2020
  • Fundamental
  • Price
  • WLDN $38.09
  • KROS $10.86
  • Analyst Decision
  • WLDN Strong Buy
  • KROS Buy
  • Analyst Count
  • WLDN 3
  • KROS 11
  • Target Price
  • WLDN $44.33
  • KROS $45.33
  • AVG Volume (30 Days)
  • WLDN 121.3K
  • KROS 2.0M
  • Earning Date
  • WLDN 03-06-2025
  • KROS 02-26-2025
  • Dividend Yield
  • WLDN N/A
  • KROS N/A
  • EPS Growth
  • WLDN 802.09
  • KROS N/A
  • EPS
  • WLDN 1.63
  • KROS N/A
  • Revenue
  • WLDN $577,414,000.00
  • KROS $651,000.00
  • Revenue This Year
  • WLDN N/A
  • KROS $303.39
  • Revenue Next Year
  • WLDN $7.28
  • KROS N/A
  • P/E Ratio
  • WLDN $23.37
  • KROS N/A
  • Revenue Growth
  • WLDN 23.47
  • KROS 8037.50
  • 52 Week Low
  • WLDN $18.37
  • KROS $9.78
  • 52 Week High
  • WLDN $50.00
  • KROS $73.00
  • Technical
  • Relative Strength Index (RSI)
  • WLDN 45.58
  • KROS 20.25
  • Support Level
  • WLDN $34.73
  • KROS $9.78
  • Resistance Level
  • WLDN $39.09
  • KROS $16.49
  • Average True Range (ATR)
  • WLDN 1.18
  • KROS 0.92
  • MACD
  • WLDN 0.21
  • KROS 0.97
  • Stochastic Oscillator
  • WLDN 76.36
  • KROS 14.52

About WLDN Willdan Group Inc.

Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: